Spike Protein News and Research

RSS

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

A group of researchers from the United States discovered that the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce the formation of highly inflammatory blood clots amenable to neutralization by a fibrin-targeting monoclonal antibody – opening the door for a completely new strategy to reduce thrombotic inflammation in coronavirus disease 2019 (COVID-19).

17 Oct 2021

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

The efficacy and safety of a DNA-based vaccine are investigated, finding that the unique vaccine imparts a robust and long-lasting immunogenic response.

15 Oct 2021

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.

15 Oct 2021

Increased transmission in open spike conformations of SARS-CoV-2 variants

Researchers from Yale University and the University of Texas have collaborated to investigate mutations in some VOCs.

14 Oct 2021

Mutation of cysteine residues in NRP1 reduces SARS-CoV-2 spike protein entry into cells

Researchers have been investigating altered protein conformations in variants of concern to provide further insight for future therapies against COVID-19.

14 Oct 2021

Assay for the sensitive and specific identification of SARS-CoV-2 Delta variant

Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).

14 Oct 2021

COVID-19 booster for immunosuppressed patients with inflammatory bowel disease

Researchers have published correspondence detailing the reasoning behind providing a third booster dose to patients with inflammatory bowel disease that have been treated with drugs that can reduce the response to the COVID-19 vaccines.

14 Oct 2021

Small portion of COVID-19 patients infectious long-term

In late December 2019, a novel pneumonia-like lung infection was reported in the Chinese province of Hubei. This, in turn, led to the ongoing coronavirus disease-19 (COVID-19) pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to SARS (Severe Acute Respiratory Syndrome) and MERS (the Middle East Respiratory Syndrome Coronavirus).

13 Oct 2021

Anti-rheumatic drug as a potential candidate for treating COVID-19

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces inflammatory cytokine storms. But an FDA-approved anti-rheumatic drug, Auranofin, used to treat autoimmune and infectious diseases, may also help serve as an antiviral treatment for COVID-19 infection.

13 Oct 2021

COVID-19 vaccination induces transient increase in cellular and antibody responses to S1 antigenic sequence

Scientists have characterized T-cell, B-cell, and IgG responses to S antigenic sequences to evaluate vaccine effectiveness.

13 Oct 2021

How long does natural immunity produced by SARS-CoV-2 infection last?

A new study posted to the bioRxiv* preprint server followed the adaptive immune response in convalescent patients from Swedish and Italian cohorts—which had earlier shown long-lasting adaptive immune responses to the G614 strain—for 15 months. Here, specific antibody levels and neutralizing antibody titers were tested against variants of concern (VOCs).

12 Oct 2021

Scientists develop an extremely potent siRNA with broad activity against SARS-CoVs

Researchers in Germany have developed a promising approach to suppressing the viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

12 Oct 2021

Rapid measurement of SARS-CoV-2 spike T-cells

Researchers measure SARS-CoV-2 T-cell responses in individuals vaccinated or in those who developed immunity from a prior natural infection.

12 Oct 2021

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Researchers review diverse computational methods for drug/inhibitor design and enzymes as potential targets for inhibitors to treat coronaviruses diseases.

12 Oct 2021

A new bacterial two-hybrid assay to study SARS-CoV-2 interactome

Recently, scientists have developed a bacterial two-hybrid (B2H) system to study the PPIs of SARS-CoV-2 in a heterologous non-eukaryotic system. This study is available on the bioRxiv* preprint server. Put simply, the B2H system could be used to analyze the SARS-CoV-2 proteome.

11 Oct 2021

Spike Protein News and Research

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

Increased transmission in open spike conformations of SARS-CoV-2 variants

Mutation of cysteine residues in NRP1 reduces SARS-CoV-2 spike protein entry into cells

Assay for the sensitive and specific identification of SARS-CoV-2 Delta variant

COVID-19 booster for immunosuppressed patients with inflammatory bowel disease

Small portion of COVID-19 patients infectious long-term

Anti-rheumatic drug as a potential candidate for treating COVID-19

COVID-19 vaccination induces transient increase in cellular and antibody responses to S1 antigenic sequence

How long does natural immunity produced by SARS-CoV-2 infection last?

Scientists develop an extremely potent siRNA with broad activity against SARS-CoVs

Rapid measurement of SARS-CoV-2 spike T-cells

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

A new bacterial two-hybrid assay to study SARS-CoV-2 interactome

New compound can prevent SARS-CoV-2 and related coronaviruses from entering cells

Analysis of SARS-CoV-2 Delta variant transmissibility across New England, USA

COVID-19 vaccination elicits broader antibody response to SARS-CoV-2 spike than infection

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

Delta variant exhibits immune evasion, enhanced cell entry, and augmented syncytium formation

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News